Company intelligence / Profile preview
Proximagen
London, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Proximagen was a UK-based biotech/pharma company focused on developing novel therapeutics—primarily small molecules—for central nervous system diseases and inflammatory conditions. Its pipeline included candidates targeting CXCR4, VAP‑1, M1 and serotonin receptors. The company initiated several clinical trials but ultimately discontinued all programs and was dissolved in October 2020.[3][4][5]
- Therapeutic areas
- RheumatologyOphthalmologyEndocrinologyOncologyNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
H. Lundbeck A/S (strategic partnership)Altacor Limited (collaborative R&D agreement for glaucoma program)BrainCells Inc. (“sabcomeline” sale/purchase agreement)
Beyond the preview
Go deeper on Proximagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proximagen.